As AAV programs progress into larger clinical studies and commercial manufacturing, decisions made early in development can have far-reaching consequences for product safety, process robustness, and regulatory readiness. This webinar explores emerging scientific and regulatory perspectives on AAV quality, including the FDA Advanced Manufacturing Technology (AMT) designation, impurity control, and how cell-line engineering, process development, and manufacturing strategy can work together to strengthen product safety from the start.